-
Sacituzumab govitecan, sold
under the
brand name
Trodelvy by
Gilead Sciences, is a Trop-2-directed
antibody and
topoisomerase inhibitor drug conjugate...
-
inhibitor mTNBC -PD-L1: 1st line: single-agent chemo; 3rd line:
sacituzumab govitecan mTNBC +BRCA:
patients previously treated with
chemotherapy in the neoadjuvant...
- "IrinotecanPathway_WP229". NK012, a
nanodevice formulation of SN-38
Sacituzumab govitecan, an antibody-drug
conjugate that uses SN-38 as the
cytotoxic drug. "CAMPTOSAR-...
- survival. In
April 2021, the FDA
granted accelerated approval to
sacituzumab govitecan for
people with
locally advanced or
metastatic urothelial cancer (mUC)...
-
target for late-stage
diseases This
antigen is the
target of
sacituzumab govitecan and
datopotamab deruxtecan (Dato-DXd), both antibody-drug conjugates....
-
coronavirus SARS-CoV-2
Pegvaliese (Palynziq) for
phenylketonuria Sacituzumab govitecan (Trodelvy) for
urinary tract cancers The
graduate program at
Scripps Research...
-
Washkowitz S,
Sharkey RM,
Wegener WA,
Kalinsky K (February 2019). "Sacituzumab
Govitecan-hziy in
Refractory Metastatic Triple-Negative
Breast Cancer". N Engl J...
- share),
gaining control of the
cancer treatment Trodelvy (Sacituzumab
govitecan-hziy) – a first-in-class Trop-2 antibody-drug conjugate. In December,...
-
phase III
trials for
pediatric leukemia.[citation needed]
Sacituzumab govitecan (IMMU-132 / Trodelvy) is an anti-Trop-2-SN-38 antibody-drug conjugate...
- 2023.
Retrieved 28 June 2023 – via PR Newswire. "Trodelvy-
sacituzumab govitecan powder, for solution". DailyMed.
Archived from the
original on 20 March...
